Roche Seeks Leading Role For PD-L1 Checkpoint Inhibitor In Bladder Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
In a just-released ASCO abstract, Roche/Genentech’s MPDL3280A demonstrates 50% objective response rate in biomarker+ patients and no new safety signals in Phase I bladder cancer study. Unmet need and a strong efficacy signal support prioritizing this new indication, says Genentech’s Dan Chen.